M2-polarized macrophages contribute to neovasculogenesis, leading to relapse of oral cancer following radiation

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Okubo, Makiko ^a   Kioi, Mitomu ^a   Nakashima, Hideyuki ^a   Sugiura, Kei ^a   Mitsudo, Kenji ^a   Aoki, Ichiro ^a   Taniguchi, Hideki ^a   Tohnai, Iwai ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; ITGAM PROTEIN, HUMAN; TUMOR MARKER;

ANIMAL; BONE MARROW CELL; CANCER STAGING; CELL HYPOXIA; DRUG SCREENING; GENETICS; HUMAN; MACROPHAGE; MOUSE; MOUTH TUMOR; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RADIATION RESPONSE; RECURRENT DISEASE; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR RECURRENCE;

ANIMALS; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CD11B ANTIGEN; CELL HYPOXIA; CELL LINE, TUMOR; HUMANS; MACROPHAGES; MICE; MOUTH NEOPLASMS; MYELOID CELLS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; RECURRENCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84976394990     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep27548     Document Type: Article

References (45)

1. Folkman, J. Tumour Angiogenesis: Therapeutic Implications. New Engl. J. Med. 285, 1182-1186 (1971).
2. Bergers, G. & Hanahan, D. Modes of resistance to anti-Angiogenic therapy. Nat. Rev. Cancer. 8, 592-603 (2008).
3. Paez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumours to increased local invasion and distant metastasis. Cancer Cell. 15, 220-231 (2009).
4. Asahara, T. et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science (New York, NY). 275, 964-967 (1997).
5. Kioi, M. et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest. 120, 694-705 (2010).
6. Kozin, S. V. et al. Recruitment of myeloid but not endothelial precursor cells facilitates tumour regrowth after local irradiation. Cancer Res. 70, 5679-5685 (2010).
7. Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumour progression and metastasis. Cell. 141, 39-51 (2010).
8. Mantovani, A., Sica, A., Allavena, P., Garlanda, C. & Locati, M. Tumour-Associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum. Immunol. 70, 325-330 (2009).
9. Ruffell, B., Affara, N. I. & Coussens, L. M. Differential macrophage programming in the tumour microenvironment. Trends in immunology. 33, 119-126 (2012).
10. Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253-268 (2012).
11. Sica, A., Schioppa, T., Mantovani, A. & Allavena, P. Tumour-Associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer. 42, 717-727 (2006).
12. Lan, C. et al. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat. 12, 259-267 (2013).
13. Sugimoto, M. et al. Prognostic impact of M2 macrophages at neural invasion in patients with invasive ductal carcinoma of the pancreas. Eur. J. Cancer. 50, 1900-1908 (2014).
14. Ding, P., Wang, W., Wang, J., Yang, Z. & Xue, L. Expression of tumour-Associated macrophage in progression of human glioma. Cell Biochem Biophys. 70, 1625-1631 (2014).
15. Balermpas, P. et al. Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences. Br. J. Cancer. 111, 1509-1518 (2014).
16. Costa, N. L. et al. Tumour-Associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma. Oral Oncol. 49, 216-223 (2013).
17. Du, R. et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumour angiogenesis and invasion. Cancer Cell. 13, 206-220 (2008).
18. Ahn, G. O. et al. Transcriptional activation of hypoxia-inducible factor-1 (HIF-1) in myeloid cells promotes angiogenesis through VEGF and S100A8. Proc Natl Acad Sci USA 111, 2698-2703 (2014).
19. Almand, B. et al. Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer. The Journal of Immunology. 166, 678-689 (2001).
20. Bronte, V. et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+ ) T cells. Blood. 96, 3838-3846 (2000).
21. Milas, L., Hunter, N. & Peters, L. J. The tumour bed effect: dependence of tumour take, growth rate, and metastasis on the time interval between irradiation and tumour cell transplantation. Int. J. Radiat. Oncol. Biol. Phys. 13, 379-383 (1987).
22. De Palma, M. et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumour vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 8, 211-226 (2005).
23. Husain, S. R., Joshi, B. H. & Puri, R. K. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int. J. Cancer. 92, 168-175 (2001).
24. Kioi, M. et al. IL-13 cytotoxin has potent antitumour activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma. Int. J. Cancer. 124, 1440-1448 (2009).
25. Brown, C. E. et al. Bioactivity and Safety of IL13Ralpha2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. Clin. Cancer. Res. 21, 4062-4072 (2015).
26. Schiechl, G. et al. Tumour development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+ CD11b(high) Gr1(low) macrophages. J. Clin. Invest. 121, 1692-1708 (2011).
27. Fichtner-Feigl, S., Strober, W., Kawakami, K., Puri, R. K. & Kitani, A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat. Med. 12, 99-106 (2006).
28. Ahn, G. O. et al. Inhibition of Mac-1 (CD11b/CD18) enhances tumour response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci USA 107, 8363-8368 (2010).
29. Cho, H. J. et al. Bone marrow-derived, alternatively activated macrophages enhance solid tumour growth and lung metastasis of mammary carcinoma cells in a Balb/C mouse orthotopic model. Breast Cancer Res. 14, R81 (2012).
30. Xu, J. et al. CSF1R signaling blockade stanches tumour-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 73, 2782-2794 (2013).
31. Laoui, D., Van Overmeire, E., De Baetselier, P., Van Ginderachter, J. A. & Raes, G. Functional Relationship between Tumour-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression. Front Immunol. 5, 489 (2014).
32. Pyonteck, S. M. et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264-1272 (2013).
33. Welford, A. F. et al. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J. Clin. Invest. 121, 1969-1973 (2011).
34. Parker, K. H., Beury, D. W. & Ostrand-Rosenberg, S. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumour Microenvironment. Adv. Cancer Res. 128, 95-139 (2015).
35. Sica, A. & Mantovani, A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122, 787-795 (2012).
36. Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer. 4, 71-78 (2004).
37. Chen, J. J. et al. Tumour-Associated macrophages: the double-edged sword in cancer progression. J Clin Oncol. 23, 953-964 (2005).
38. Chanmee, T., Ontong, P., Konno, K. & Itano, N. Tumour-Associated macrophages as major players in the tumour microenvironment. Cancers (Basel). 6, 1670-1690 (2014).
39. Cieslewicz, M. et al. Targeted delivery of proapoptotic peptides to tumour-Associated macrophages improves survival. Proc Natl Acad Sci USA 110, 15919-15924 (2013).
40. Puri, R. K. et al. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood. 87, 4333-4339 (1996).
41. Davis, M. J. et al. Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection. MBio. 4, e00264-00213 (2013).
42. Chamberlain, L. M., Godek, M. L., Gonzalez-Juarrero, M. & Grainger, D. W. Phenotypic non-equivalence of murine (monocyte-) macrophage cells in biomaterial and inflammatory models. J. Biomed. Mater. Res. A. 88, 858-871 (2009).
43. Atochina, O., Da'dara, A. A., Walker, M. & Harn, D. A. The immunomodulatory glycan LNFPIII initiates alternative activation of murine macrophages in vivo. Immunology. 125, 111-121 (2008).
44. Jakubzick, C., Kunkel, S. L., Joshi, B. H., Puri, R. K. & Hogaboam, C. M. Interleukin-13 Fusion Cytotoxin Arrests Schistosoma mansoni Egg-Induced Pulmonary Granuloma Formation in Mice. The American Journal of Pathology. 161, 1283-1297 (2002).
45. Nakashima, H., Fujisawa, T., Husain, S. R. & Puri, R. K. Interleukin-13 receptor alpha2 DNA prime boost vaccine induces tumour immunity in murine tumour models. J Transl Med. 8, 116 (2010).